![Vivek Subbiah: Pan-KRAS inhibitors have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.](https://oncodaily.com/pub/uploads/2023/07/Vivek-Subbiah-e1703016475550-1280x886.jpeg)
Photo taken from Vivek Subbiah/LinkedIn
Aug 20, 2023, 17:41
Vivek Subbiah: Pan-KRAS inhibitors have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.
According to Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute on LinkedIn:
“Pan-KRAS inhibitors, such as the one described here in Nature have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers. Such an exciting space.”
For the article click here.
Source: Vivek Subbiah/LinkedIn